For Q3 2026, analysts expect Personalis to report revenue of $21.54 million and an EPS loss of $0.26, with the stock currently trading at $16.00, slightly below the $16.25 Tempus AI buyout price.
The primary focus for investors remains the finalization of this $1.5 billion acquisition and any regulatory updates regarding the deal.
Beyond the merger, the market is tracking the adoption of the NeXT Personal MRD test, which has demonstrated significant volume growth and expanded Medicare coverage visibility. While revenue is projected to grow nearly 49% year-over-year, Personalis continues to manage high operating losses and margin compression during its strategic pivot.